Ash is a member-partner in Proception and Chief Scientific Officer and Vice President at Jeiven Pharmaceutical Consulting Inc. (JPC). JPC provides expert advice in the fields of Quality, Regulatory Affairs, Formulations, Process Development, Manufacturing, Packaging and Labeling of Clinical and Commercial Supplies. For JPC Ash provides expertise in the areas of medical devices, pharmaceuticals, combination drug/devices, and in-vitro diagnostics. Prior to JPC, Ash was Chief Strategic Officer at Vyteris, a publicly traded drug delivery company that was a spin-out from BD and where he was part of the management team along with Vince and Mike, where his efforts were focused on Vyteris’ Smart Patch technology, leading the development of Vyteris’ active transdermal drug delivery platform technology which resulted in approval of first-ever pre-filled active patch combination drug/device product by the FDA. Prior to joining Vyteris, Ash worked at BD where he held positions as Program Manager for integrated drug delivery and diagnostic system and Manager, Intelligent Systems Development for BD's Consumer Healthcare Business. Ash is a member of the Institutional Review Boards at the Kessler Foundation, NJIT, and the New York Blood Center. Ash is also a Fellow of AIMBE (the American Institute for Medical and Biological Engineering). Ash holds a B. Tech. degree in Electrical Engineering from the Indian Institute of Technology in Kanpur, India. A graduate of Rensselaer Polytechnic Institute he holds M.S. degrees in Biomedical Engineering and Computer & Systems Engineering and a Ph.D. degree in Biomedical Engineering.
Mike is a member-partner in Proception and heads up Corporate Development, Finance & Administration and Liaison to the Strategics. Previously Mike has served as CFO, COO, interim CEO and Board member for a number of companies involved in the life sciences where he closed on over $500 million in funding and licensing transactions. Prior to founding Proception, Mike served as the CFO and interim CEO for Nextremity Solutions, a medical device company. Mike joined Nextremity from Manhattan Pharmaceuticals, a publicly-traded specialty pharma company, where he served as CFO, COO and Board member. Prior to Manhattan, he served as CFO for Vyteris, a publicly traded drug delivery company that was a spin-out from Becton Dickinson and where he was part of the management team along with Vince and Ash (see below). Mike also served as CFO and a Board member for EpiGenesis, a biotech company and CFO at BlueStone Capital Partners, an international investment bank and broker-dealer. Mike graduated from Hofstra University with a BBA in Accounting 1981 and received his CPA license from NYS in 1984.
Senior Advisor, US Venture Partners, a world-class venture capital fund
Senior Vice President and Managing Director at First Analysis Securities
Vince is a member-partner in Proception and an independent MedTech consultant. Prior to working with Proception, Vince was president, CEO and vice chairman of Vyteris, Inc., a publicly traded drug delivery company that was a spin-out from Becton Dickinson (BD) and where he was part of the management team along with Mike and Ash (see below). Vince joined Vyteris from BD a Fortune 500 medical technology company that manufactures and sells medical devices, instrument systems and reagents. Vince served BD most recently as senior vice president and general manager of Advanced Drug Delivery. Prior positions at BD included senior vice president and chief technology officer, sector president for technique products and president of the worldwide vascular access business. Vince holds a BSEE degree from NJIT and MS and Ph.D. degrees in bioengineering from the Tandon School of Engineering (now a division of NYU). Vince is active in the bioengineering community and has been elected to the College of Fellows of AIMBE (American Institute of Medical and Biological Engineering), and has served on AIMBE’s board of directors as chair of the Industry Council. He is a vice-chair of the Board of Trustees of NJIT and has served on the industrial advisory boards of MIT’s Center for Biomedical Engineering, John Hopkins University Bioengineering Department, the University of Utah’s Bioengineering Department, and the Georgia Institute of Technology’s Petit Institute for Bioengineering and Biosciences.